Clinical Trial Update: Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II trial investigating INC280 plus PDR001 or PDR001 alone in advanced hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cancer

Drugs mentioned

• INC280
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-07-03